This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Acadia Pharmaceuticals: Investing With No Safety Net

Stocks in this article: ACAD DEPO POZN SUPG

The following commentary comes from an independent investor or market observer as part of TheStreet's guest contributor program, which is separate from the company's news coverage.

NEW YORK ( -- It is one of the fundamental facts of Joel Greenblatt's Magic Formula Investing (MFI) screening methodology: small research pharmaceutical firms almost always show up shortly after receiving one-time windfalls such as hitting development milestones or receiving collaboration payments of some sort.

These huge shots of revenue spike profits, causing trailing 12-month returns on capital to skyrocket. At the same time, human investors realize that these payments are non-recurring, keeping the stock price at a reasonable level but creating what looks like a very low valuation (low P/E ratios, or high earnings yields). Bingo, the perfect formula for getting screened by MFI! I believe it is one of the side effects of the simple screening methodology, and it breaks the strategy's core mission of finding "great companies selling at cheap prices."

It is not just an annoyance, either -- a significant number of these stocks constitute the current small-cap (top 50 over $50 million) screen. Currently, eight of the 50 stocks can be classified as small research pharmaceutical firms -- a meaningful 16%. Some have approved products that pay royalties, some do not. Some have multiple late-stage drug candidates, some do not have a pipeline past Phase II.

One thing they all have in common is that it is extremely difficult to value them due to the inherent uncertainties in drug development. MagicDiligence generally recommends taking a "basket approach" if you want exposure to these names -- buy a little of each of them instead of dedicating a full portfolio position to one in particular.

We've looked at several recently ( DepoMed (DEPO), Pozen (POZN), and SuperGen (SUPG)), and today we'll add another to the reviewed list: Acadia Pharmaceuticals (ACAD).

Acadia falls on the high-risk side of this group. Unlike any of the aforementioned three stocks, Acadia does not have any approved products generating royalties. In fact, the company has never had a product approved! Acadia relies on occasional milestone payments, research grants, and issuing new equity to fund its operations. The payment that got the stock into MFI was recognition of about $35 million in deferred revenue from the October 2010 termination of its partnership with Biovail for lead drug candidate Pimavanserin. This occurred after Biovail was merged into Valeant (VRX).

1 of 3

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,030.21 +6.04 0.03%
S&P 500 2,081.88 -0.29 -0.01%
NASDAQ 4,773.4720 +8.0480 0.17%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs